{"id":"NCT04278417","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy","officialTitle":"A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-19","primaryCompletion":"2023-10-30","completion":"2024-08-19","firstPosted":"2020-02-20","resultsPosted":"2024-08-20","lastUpdate":"2025-07-04"},"enrollment":689,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Proliferative Diabetic Retinopathy"],"interventions":[{"type":"BIOLOGICAL","name":"Brolucizumab 6 mg","otherNames":["RTH258"]},{"type":"PROCEDURE","name":"Panretinal photocoagulation laser","otherNames":["PRP"]}],"arms":[{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL"},{"label":"Panretinal photocoagulation laser Arm","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week 54.","primaryOutcome":{"measure":"Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study Eye","timeFrame":"Baseline, Week 54","effectByArm":[{"arm":"Brolucizumab 6 mg","deltaMin":0.2,"sd":0.72},{"arm":"Panretinal Photocoagulation Laser Arm","deltaMin":-4.2,"sd":0.73}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":120,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","India","Japan","Mexico","Philippines","Puerto Rico","Russia","South Korea","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":96,"n":347},"commonTop":["Vitreous haemorrhage - Study eye","COVID-19","Vitreous haemorrhage - Fellow eye","Hypertension","Cataract - Study eye"]}}